Nonmyeloablative transplantation with or without alemtuzumab:: comparison between 2 prospective studies in patients with lymphoproliferative disorders

被引:177
作者
Pérez-Simón, JA
Kottaridis, PD
Martino, R
Craddock, C
Caballero, D
Chopra, R
García-Conde, J
Milligan, DW
Schey, S
Urbano-Ispizua, A
Parker, A
Leon, A
Yong, K
Sureda, A
Hunter, A
Sierra, J
Goldstone, AH
Linch, DC
San Miguel, JF
Mackinnon, S
机构
[1] Hosp Univ Salamanca, Serv Hematol, Dept Hematol, Salamanca 37007, Spain
[2] UCL Hosp, London, England
[3] Hosp Santa Creu & Sant Pau, E-08025 Barcelona, Spain
[4] Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England
[5] Univ Hosp, Birmingham, W Midlands, England
[6] Hosp Clin Valencia, Valencia, Spain
[7] Christie Hosp, Manchester, Lancs, England
[8] Hosp Clin Barcelona, Barcelona, Spain
[9] Guys Hosp, London SE1 9RT, England
[10] Hosp Jerez, Cadiz, Spain
[11] Leicester Royal Infirm, Leicester, Leics, England
关键词
D O I
10.1182/blood-2002-03-0701
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although nonmyeloablative conditioning regimen transplantations (NMTs) induce engraftment of allogeneic stem cells with a low spectrum of toxicity, graft-versus-host disease (GVHD) remains a significant cause of morbidity and mortality. In vivo T-cell depletion, using alemtuzumab, has been shown to reduce the incidence of GVHD. However, this type of maneuver, although reducing GVHD, may have an adverse impact on disease response, because NMTs exhibit their antitumor activity by relying on a graft-versus-malignancy effect. To explore the efficacy of alemtuzumab compared with methotrexate (MTX) for GVHD prophylaxis, we have compared the results in 129 recipients of a sibling NMT enrolled in 2 prospective studies for chronic lymphoproliferative disorders. Both NMTs were based on the same combination of fludarabine and melphalan, but the United Kingdom regimen (group A) used cyclosporin A plus alemtuzumab, whereas the Spanish regimen (group B) used cyclosporin A plus MTX for GVHD prophylaxis. Patients receiving alemtuzumab had a higher incidence of cytomegalovirus (CMV) reactivation (85% versus 24%, P < .001) and a significantly lower incidence of acute GVHD (21.7% versus 45.1%, P = .006) and chronic GVHD (5% versus 66.7%, P < .001). Twenty-one percent of patients in group A and 67.5% in group B had complete or partial responses 3 months after transplantation (P < .001). Eighteen patients in group A received donor lymphocyte infusions (DLIs) to achieve disease control. At last follow-up there was no difference in disease status between the groups with 71% versus 67.5% (P = .43) of patients showing complete or partial responses in groups A and B, respectively. No significant differences were observed in event-free or overall survival between the 2 groups. In conclusion, alemtuzumab significantly reduced GVHD but its use was associated with a higher incidence of CMV reactivation. Patients receiving alemtuzumab often required DLIs to achieve similar tumor control but the incidence of GVHD was not significantly increased after DILL (C) 2002 by The American Society of Hematology.
引用
收藏
页码:3121 / 3127
页数:7
相关论文
共 49 条
[1]   BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA IN 1ST CHRONIC PHASE - IMPORTANCE OF A GRAFT-VERSUS-LEUKEMIA EFFECT [J].
APPERLEY, JF ;
MAURO, FR ;
GOLDMAN, JM ;
GREGORY, W ;
ARTHUR, CK ;
HOWS, J ;
ARCESE, W ;
PAPA, G ;
MANDELLI, F ;
WARDLE, D ;
GRAVETT, P ;
FRANKLIN, IM ;
BANDINI, G ;
RICCI, P ;
TURA, S ;
IACONE, A ;
TORLONTANO, G ;
HEIT, W ;
CHAMPLIN, R ;
GALE, RP .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 69 (02) :239-245
[2]   BONE-MARROW TRANSPLANTATION [J].
ARMITAGE, JO .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (12) :827-838
[3]   High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions [J].
Badros, A ;
Barlogie, B ;
Morris, C ;
Desikan, R ;
Martin, SR ;
Munshi, N ;
Zangari, M ;
Toor, A ;
Cottler-Fox, M ;
Fassas, A ;
Aniassie, E ;
Schichman, S ;
Tricot, G .
BLOOD, 2001, 97 (09) :2574-2579
[4]   Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect [J].
Bertz, H ;
Burger, JA ;
Kunzmann, R ;
Mertelsmann, R ;
Finke, J .
LEUKEMIA, 1997, 11 (02) :281-283
[5]   BONE-MARROW TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES IN PATIENTS AGED 30 YEARS OR OLDER [J].
BLUME, KG ;
FORMAN, SJ ;
NADEMANEE, AP ;
ODONNELL, MR ;
SNYDER, DS ;
FAHEY, JL ;
SNIECINSKI, IJ ;
FINDLEY, DO ;
LIPSETT, JA ;
ZAIA, JA ;
METTER, GE ;
HILL, LR .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (10) :1489-1492
[6]   Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients [J].
Boeckh, M ;
Bowden, RA ;
Gooley, T ;
Myerson, D ;
Corey, L .
BLOOD, 1999, 93 (05) :1781-1782
[7]   Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study [J].
Boeckh, M ;
Gooley, TA ;
Myerson, D ;
Cunningham, T ;
Schoch, G ;
Bowden, RA .
BLOOD, 1996, 88 (10) :4063-4071
[8]  
BORTIN M M, 1992, Journal of the American Medical Association, V268, P607, DOI 10.1001/jama.268.5.607
[9]   Comparison between antigenemia and a quantitative-competitive polymerase chain reaction for the diagnosis of cytomegalovirus infection after heart transplantation [J].
Camargo, LFA ;
Uip, DE ;
Simpson, AAG ;
Caballero, O ;
Stolf, NAG ;
Vilas-Boas, LS ;
Pannuti, CS .
TRANSPLANTATION, 2001, 71 (03) :412-417
[10]   High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution [J].
Chakrabarti, S ;
Mackinnon, S ;
Chopra, R ;
Kottaridis, PD ;
Peggs, K ;
O'Gorman, P ;
Chakraverty, R ;
Marshall, T ;
Osman, H ;
Mahendra, P ;
Craddock, C ;
Waldmann, H ;
Hale, G ;
Fegan, CD ;
Yong, K ;
Goldstone, AH ;
Linch, DC ;
Milligan, DW .
BLOOD, 2002, 99 (12) :4357-4363